Revolution Medicines (NASDAQ:RVMD) Sees Large Volume Increase - Still a Buy?

Key Points

• Positive Phase III data for daraxonrasib showed a meaningful survival benefit, triggering a sharp rally and positioning the company to pursue global regulatory filings.
• The company priced concurrent upsized offerings totalling about $2.0 billion (common stock at $142 and $500M of 0.50% convertible notes) to fund R&D and commercialization—this boosts liquidity but increases dilution and coincides with notable insider selling.
• Analysts and institutions remain bullish (consensus Buy and ~94% institutional ownership), yet the MarketBeat average price target (~$78.94) is far below the current share price and trading volume has recently spiked.

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) saw strong trading volume on Wednesday . 2,357,874 shares traded hands during mid-day trading, a decline of 30% from the previous session's volume of 3,348,162 shares.The stock last traded at $149.0580 and had previously closed at $147.01.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Phase III pancreatic cancer data for daraxonrasib showed a meaningful survival benefit, which triggered a sharp rally and positions the company to pursue global regulatory filings — a clear commercial/catalyst positive. RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
• Positive Sentiment: Analyst/broker support is reinforcing the move — Wedbush reaffirmed an Outperform and recent coverage (including bullish takes on daraxonrasib) has kept buy-side momentum and price targets elevated. Revolution Medicines' (RVMD) "Outperform" Rating Reaffirmed at Wedbush
• Positive Sentiment: Unusual options flow: notable uptick in call buying suggests traders are positioning for further upside after the clinical readout. Options activity / market coverage
• Neutral Sentiment: Financing priced: the company upsized and priced concurrent offerings (common stock at $142 and $500M 0.50% convertible notes), raising roughly $2.0B of capacity to fund R&D and potential commercialization — improves liquidity but shifts capital structure. Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings
• Negative Sentiment: Dilution and insider selling risk: the equity offering increases share count and Quiver/filings show substantial insider sales and institutional rebalancing in recent quarters, which could cap near-term upside if selling persists. Quiver Quant / offering and insider summary

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Benchmark reiterated an "overweight" rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Jefferies Financial Group assumed coverage on shares of Revolution Medicines in a research report on Monday, March 16th. They issued a "buy" rating for the company. Evercore reissued an "outperform" rating on shares of Revolution Medicines in a research report on Tuesday. UBS Group assumed coverage on shares of Revolution Medicines in a research report on Friday, February 27th. They issued a "buy" rating for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Four analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Revolution Medicines presently has a consensus rating of "Buy" and an average price target of $78.94.

Revolution Medicines Trading Up 1.8%

The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. The company has a market cap of $29.66 billion, a price-to-earnings ratio of -25.33 and a beta of 1.01. The company's fifty day moving average price is $99.92 and its two-hundred day moving average price is $84.28.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.30). During the same quarter last year, the business earned ($1.12) EPS. Research analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Stephen Michael Kelsey sold 4,302 shares of the firm's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the completion of the sale, the insider owned 295,398 shares of the company's stock, valued at $29,386,193.04. This trade represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jack Anders sold 2,753 shares of the firm's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $273,868.44. Following the completion of the sale, the chief financial officer directly owned 125,512 shares of the company's stock, valued at approximately $12,485,933.76. This represents a 2.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 64,592 shares of company stock valued at $6,488,732 over the last quarter. Company insiders own 8.20% of the company's stock.

Hedge Funds Weigh In On Revolution Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of RVMD. Nextech Invest Ltd. boosted its stake in Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after acquiring an additional 1,304,347 shares during the last quarter. Millennium Management LLC boosted its stake in Revolution Medicines by 681.8% in the first quarter. Millennium Management LLC now owns 156,353 shares of the company's stock valued at $5,529,000 after acquiring an additional 136,353 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Revolution Medicines by 14.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company's stock valued at $10,615,000 after acquiring an additional 37,345 shares during the last quarter. Invesco Ltd. boosted its stake in Revolution Medicines by 19.3% in the second quarter. Invesco Ltd. now owns 227,019 shares of the company's stock valued at $8,352,000 after acquiring an additional 36,760 shares during the last quarter. Finally, Jump Financial LLC boosted its stake in Revolution Medicines by 87.9% in the second quarter. Jump Financial LLC now owns 15,258 shares of the company's stock valued at $561,000 after acquiring an additional 7,137 shares during the last quarter. 94.34% of the stock is owned by institutional investors.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.